Short Interest in Oruka Therapeutics, Inc. (NASDAQ:ORKA) Expands By 22.4%

Oruka Therapeutics, Inc. (NASDAQ:ORKA) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totaling 5,537,531 shares, an increase of 22.4% from the March 31st total of 4,522,980 shares. Based on an average trading volume of 1,369,348 shares, the short-interest ratio is presently 4.0 days. Approximately 14.6% of the shares of the stock are short sold.

Oruka Therapeutics Stock Down 8.5%

Shares of Oruka Therapeutics stock traded down $5.83 during trading on Friday, reaching $62.58. The company’s stock had a trading volume of 3,951,109 shares, compared to its average volume of 2,088,233. Oruka Therapeutics has a 52-week low of $8.91 and a 52-week high of $91.00. The company has a market cap of $3.14 billion, a price-to-earnings ratio of -33.64 and a beta of -0.20. The firm’s 50-day moving average is $49.57 and its two-hundred day moving average is $36.87.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. On average, equities research analysts anticipate that Oruka Therapeutics will post -2.2 EPS for the current year.

Key Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Positive Phase 2a clinical readout for ORKA-001 in plaque psoriasis increases the program’s de-risking and potential value capture for the company; this is a direct product catalyst that can support longer-term upside. Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001
• Positive Sentiment: HC Wainwright materially raised EPS loss forecasts across 2026–2027 and reiterated a Buy rating with a $120 target — analysts now expect smaller quarterly losses and a narrower FY2027 loss, which supports the investment thesis and implies substantial upside from current levels. HC Wainwright raises estimates for Oruka Therapeutics
• Positive Sentiment: Stifel Nicolaus maintained its Buy rating on ORKA, providing additional sell?side validation and supporting investor confidence in the company’s pipeline and outlook. Stifel Nicolaus Keeps Their Buy Rating on Oruka Therapeutics (ORKA)
• Neutral Sentiment: Seeking Alpha published a detailed slideshow of interim EVERLAST?A study results for ORKA?001, useful for investors wanting deeper clinical context but not new headline data. Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001
• Neutral Sentiment: Oruka was noted in a roundup of high?momentum small caps, which can draw retail attention but is not a direct fundamental driver. 5 Small-Cap Stocks That Are On Fire Right Now
• Negative Sentiment: The company priced an upsized $700M public offering at $72.50 per share — the size and pricing increase share supply and introduce meaningful dilution risk, which likely triggered selling pressure despite positive news and analyst upgrades. This is the most immediate bearish catalyst for share performance. Oruka Therapeutics prices upsized $700M public offering at $72.50 per share

Insider Activity

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the sale, the chief executive officer owned 927,309 shares of the company’s stock, valued at $38,297,861.70. This trade represents a 0.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $66.12, for a total value of $462,840.00. Following the completion of the sale, the insider directly owned 33,377 shares in the company, valued at approximately $2,206,887.24. The trade was a 17.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 23,765 shares of company stock worth $1,089,745. Insiders own 24.69% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Fairmount Funds Management LLC increased its stake in Oruka Therapeutics by 9.9% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock worth $71,252,000 after purchasing an additional 333,340 shares during the period. Secure Asset Management LLC purchased a new position in Oruka Therapeutics in the 4th quarter worth approximately $2,475,000. Avoro Capital Advisors LLC purchased a new position in Oruka Therapeutics in the 3rd quarter worth approximately $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in Oruka Therapeutics in the 3rd quarter worth approximately $296,000. Finally, Commodore Capital LP increased its stake in Oruka Therapeutics by 23.5% in the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock worth $33,711,000 after purchasing an additional 333,340 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Guggenheim set a $200.00 price target on Oruka Therapeutics and gave the company a “buy” rating in a report on Monday. HC Wainwright raised their price target on Oruka Therapeutics from $75.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday. UBS Group raised their price target on Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday. Leerink Partners set a $120.00 price target on Oruka Therapeutics in a report on Thursday. Finally, Stifel Nicolaus increased their price objective on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $120.80.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.